Results 31 to 40 of about 2,348 (179)
Neoadjuvant Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma: Insights from Two Real-world Cases [PDF]
Acta Dermato-VenereologicaPaolo Antonetti +4 more
doaj +2 more sources
Hospital Pharmacy, 2015 The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Corey J, Medler +2 more
openaire +2 more sources
Experience with sonidegib in patients with advanced basal cell carcinoma: case reports
Drugs in Context, 2022 Sonidegib is a Hedgehog signalling pathway inhibitor approved for use in patients with advanced basal cell carcinoma (BCC) not eligible for surgery or radiotherapy.
Susana Puig +4 more
doaj +1 more source
Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma [PDF]
, 2020 The pivotal BOLT (Basal cell carcinoma Outcomes with LDE225 [sonidegib] Treatment) study established the durable efficacy and manageable toxicity of sonidegib 200 mg once daily (QD) through 42 months in patients with advanced basal cell carcinoma (BCC ...
Liu, Li +4 more
core +1 more source
, 2022 Our structure-based virtual screening of the FDA-approved drug library has revealed that sonidegib, a smoothened antagonist clinically used to treat basal cell carcinoma, is a potential c-Jun N-terminal kinase 3 (JNK3) inhibitor.
Nguyen, Ngoc Minh +13 more
core +1 more source
Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs. [PDF]
Clin Pharmacol TherDrug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Alhurayri F +10 more
europepmc +2 more sources
, 2021 Locally advanced basal cell carcinoma (laBCC) represents a rare but possible occurrence in the vast scenario of dermatological diseases. It is well known that most BCC has a pathological activation of the hedgehog pathway, making them susceptible to ...
Veronese F. +4 more
core +1 more source
, 2023 Introduction: Surgery is the standard management for most of basal cell carcinomas (BBCs). In some cases, also radiotherapy may be a valuable weapon as well as ablative and topical treatments.
Francesco Lacarrubba +17 more
core +1 more source
A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low-Risk Basal Cell Carcinoma. [PDF]
Exp DermatolNeoadjuvant treatment with oral itraconazole for two months demonstrated significant responses in low‐risk basal cell carcinomas. This effect was associated with decreased tumour angiogenesis, presenting a favourable safety profile for patients. ABSTRACT Recently, new treatment strategies have been developed for advanced or metastatic basal cell ...
Pereira RP +7 more
europepmc +2 more sources
Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial [PDF]
, 2021 Introduction Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma.
Dummer, Reinhard; https://orcid.org/ +5 more
core +1 more source